Free tool
FAERS Monitor: Hylenex Recombinant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021859 or its brand name (Hylenex Recombinant, Hyaluronidase Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
1,227
Serious
1,022
83% of reports
Hospitalization
708
Death reported
548
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue305
- abdominal discomfort298
- alopecia294
- diarrhoea282
- asthenia281
- arthralgia280
- headache279
- hypertension279
- hypersensitivity278
- hepatic enzyme increased275
- contusion271
- asthma270
- blood cholesterol increased268
- discomfort267
- dyspnoea267
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 8 |
| 2006 | 22 |
| 2007 | 27 |
| 2008 | 8 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 45 |
| 2016 | 23 |
| 2017 | 31 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 53 |
| 2021 | 67 |
| 2022 | 61 |
| 2023 | 110 |
| 2024 | 310 |
| 2025 | 232 |
| 2026 | 126 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,932 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood cholesterol increasedSignal | 268 | 99.1 | 89.1 | 25,840 |
| discomfortSignal | 267 | 75.3 | 67.7 | 19,482 |
| hepatic enzyme increasedSignal | 275 | 69.4 | 62.5 | 18,462 |
| contusionSignal | 271 | 48.4 | 43.5 | 12,550 |
| asthmaSignal | 270 | 41.0 | 36.9 | 10,541 |
| abdominal discomfortSignal | 298 | 30.5 | 27.6 | 8,527 |
| hypersensitivitySignal | 278 | 25.7 | 23.2 | 6,626 |
| alopeciaSignal | 294 | 25.7 | 23.3 | 7,009 |
| hypertensionSignal | 279 | 22.6 | 20.4 | 5,792 |
| astheniaSignal | 281 | 12.8 | 11.6 | 3,104 |
| arthralgiaSignal | 280 | 11.6 | 10.4 | 2,740 |
| dyspnoeaSignal | 267 | 8.1 | 7.3 | 1,696 |
| headacheSignal | 279 | 7.6 | 6.9 | 1,649 |
| diarrhoeaSignal | 282 | 7.5 | 6.8 | 1,629 |
| fatigueSignal | 305 | 6.7 | 6.1 | 1,535 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.